Sneaky Delivery System Revolutionizes Multiple Sclerosis Treatment

Multiple sclerosis, or MS, is an autoimmune disorder in which the immune system attacks myelin surrounding nerves. It is a debilitating disease with no cure. Luckily, as our understanding of triggers in the immune system deepens, so does the likelihood of developing more effective treatments or even a cure. A new study shows just how far we have come.

A team of scientists from Northwestern University, University Hospital Zurich in Switzerland, and University Medical Center Hamburg-Eppendorf in Germany demonstrated that resetting a patient's immune system was safe and reduced the targeting of myelin by 50%-75%. The phase 1 trial supported moving into a phase 2 trial in Switzerland after funds are raised. It is great news for patients and will likely revolutionize the way we treat autoimmune diseases and allergy medications. However, it will be a long time before it readily competes with Gilenya from Novartis (NYSE: NVS  ) . Fool contributor Maxx Chatsko breaks it down for investors in the following video.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


Read/Post Comments (6) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 25, 2013, at 8:43 PM, drdonrs wrote:

    The writer obviously is one big Fool. He has no understanding of what is currently transpiring with Questcor.Iinstead he dredges up old, discredited information which is totally full of misinformation. Insurance companies are indeed reimbursing for Acthar and that includes Aetna when the appeal process comes into play. In addition he fails to provide information regarding the latest acquisitions which includes Synacthen from Novartis. Get your story straight before you spout off wrongful information just like the soon to be decimated short community. You sound just like a Cramer disciple and that "ain't" good.

  • Report this Comment On June 26, 2013, at 8:39 AM, TMFBlacknGold wrote:

    @drdonrs

    I admit I do not follow Questcor closely, but I do not understand your concerns. I made no mention of insurance and only mentioned Acthar Gel to tie it to the new compound acquired from Novartis. I used the scientific name of Synacthen in the video.

    Maxxwell

  • Report this Comment On June 26, 2013, at 8:44 AM, NotTheDroid wrote:

    the mobile version included the bash paragraph that the FOOL uses to try and sell their Questcor report for the last 6 months.

    It looked like a part of your article. So DrDons probably assumed you too were bashing with old outdated information.

    That being said, not sure why Questcor would be mentioned by you at all. There are many prophylactic MS drugs that are at risk of a better prophylactic but there are few choices for those who still end up having an exacerbation.

    Investing community is tired of kids in their pajamas writing about biotech. While your video is somewhat innocent, it's still misguided and shows a severe lack of pharmaceutical knowledge.

  • Report this Comment On June 26, 2013, at 1:27 PM, TMFBlacknGold wrote:

    @NotTheDroid

    Sorry you consider me a "kid in pajamas", but everyone has to start somewhere. I do have a degree in the field, although I am certainly not an expert.

    Maxxwell

  • Report this Comment On June 26, 2013, at 3:03 PM, ctsolomonmd wrote:

    I think this company has a strong portfolio and significant growth potential. They have maybe 35 % of the MS market. They have multiple products with different drug delivery options.

    I own the stock but a balanced position( not heavily weighted). There is always the possibility of complications as with any drug and health care in general is going to get an overhaul and drug companies may take a hit like everyone else across the healthcare board.

    All in all strong company with positive free cash flow/ share.

    Cts

  • Report this Comment On June 27, 2013, at 7:54 AM, NotTheDroid wrote:

    Maxxwell,

    Not you necessarily, but there are too many kids in pajamas articles on MF and SA.

    Investment community is leery of any blogger nowadays. Too many manipulative posts.

    Your blogs and article history does show you are off to a decent start overall.

    Good luck in your investments.

Add your comment.

DocumentId: 2508758, ~/Articles/ArticleHandler.aspx, 4/18/2014 12:19:25 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement